361 Capital’s Genomic Health, Inc. GHDX Stock Holding History

361 Capital’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-31,076	Closed	-$1.81M	–	406
2019 Q2	$1.81M	Sell	31,076 -2,207	-7%	-$131K	0.32%	162
2019 Q1	$2.33M	Buy	33,283 +3,146	+10%	+$233K	0.4%	141
2018 Q4	$1.94M	Buy	+30,137	New	+$2.11M	0.4%	140

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

361 Capital's GHDX Position: Q3 2019 in Review

361 Capital sold out of Genomic Health, Inc. (GHDX) in Q3 2019, closing a stake of 31,076 shares — an estimated $1.81M sold.

361 Capital first reported a position in GHDX in Q4 2018 and held it in 3 quarters. The position peaked at $2.33M in Q1 2019. 221 funds tracked by Wall St. Rank hold GHDX as of Q3 2019.

361 Capital reported no remaining Genomic Health, Inc. position as of Q3 2019 after selling out during the quarter.
361 Capital sold 31,076 Genomic Health, Inc. shares in Q3 2019, an estimated $1.81M.
361 Capital first reported a position in Genomic Health, Inc. in Q4 2018 and held it in 3 quarters.
361 Capital's Genomic Health, Inc. position peaked at $2.33M in Q1 2019.
221 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q3 2019.

Based on 361 Capital's 13F filing for Q3 2019, filed 14 Nov 2019.